Vimarsana
Biggest News Aggregation in the World

Page 3 - Greg Marose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Greg Marose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Greg Marose Today - Breaking & Trending Today

Acacia Research Announces New Leadership Appointments - Vimarsana News

Acacia Research Announces New Leadership Appointments

15.03.2022 - Martin D. McNulty, Jr., Former CEO of Starboard Value Acquisition Corp., Joins as Chief Operating Officer and Head of M&AWesley Golby, Who Served as Director of Research, Promoted to Chief Investment OfficerNEW YORK, NY / ACCESSWIRE / March 15, 2022 ...

Acacia Research Announces New Leadership Appointments - Vimarsana News

Acacia Research Announces New Leadership Appointments

Press release content from Accesswire. The AP news staff was not involved in its creation.

Source: apnews.com
Acacia Research Corporation: Acacia Research Announces New Leadership Appointments - Vimarsana News

Acacia Research Corporation: Acacia Research Announces New Leadership Appointments

Martin D. McNulty, Jr., Former CEO of Starboard Value Acquisition Corp., Joins as Chief Operating Officer and Head of M&AWesley Golby, Who Served as Director of Research, Promoted to Chief Investment OfficerNEW

PR News | Longacre Square, Brunswick Work Hasbro Proxy Battle - Vimarsana News

PR News | Longacre Square, Brunswick Work Hasbro Proxy Battle

Ongacre Square Partners handles media for Alta Fox Capital Management, which is pressing Hasbro Inc. to spin off its gaming unit.

CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis - Vimarsana News

CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Press release content from Business Wire. The AP news staff was not involved in its creation. CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis May 7, 2021 GMT LOS ANGELES--(BUSINESS WIRE)--May 7, 2021-- CytRx Corporation (OTCQB: CYTR) (“CytRx”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) (“Orphazyme”) announced that the ORARIALS-01 pivotal trial for arimoclomol in Amyotrophic Lateral Sclerosis (“ALS”) did not m...

Source: apnews.com